Lynda Katona
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lynda Katona has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Alison Button-Sloan
Melanoma Patients Australia, Melbourne, Vic 3000, Australia
1 shared publication - Allan Ben Smith
The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, NSW, Australia
1 shared publication B Pillay
School of Psychology and Psychiatry, Monash University, Clayton, Victoria, Australia
1 shared publication- Donna Milne
Cancer Experiences Research, Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, Victoria, 3000, Australia; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia, Melanoma and Skin Service, Peter MacCallum Cancer Centre, Melbourne, Australia
1 shared publication - Fiona Anne Lynch
Psychology Department Barwon Health Victoria Australia
1 shared publication - Haryana M. Dhillon
University of Sydney
1 shared publication
Latest Publications
- Open Access
- 14 September 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (9) , 2969
Feasibility and Acceptability of Fear-Less: A Stepped-Care Program to Manage Fear of Cancer Recurrence in People with Metastatic Melanoma
Immunotherapies and targeted therapies have revolutionised treatment of metastatic melanoma and improved survival rates. However, survivors treated with novel therapies are vulnerable to high levels of fear of cancer recurrence or progression (FCR). Existing FCR interventions have rarely been trialled in people with advanced cancer. The current study aimed to evaluate the acceptability and feasibility of Fear-Less: a stepped-care model to treat FCR in people with metastatic melanoma treated with immunotherapy or targeted therapy. Sixty-one outpatients with metastatic melanoma were screened using the Fear of Cancer Recurrence Inventory Short Form (FCRI-SF) and Fear of Progression Questionnaire Short Form (FoP-Q-SF). Survivors with subthreshold FCR were stratified to a self-management intervention while those with clinical levels of FCR were provided with an individual therapy, Conquer Fear. Survivor experience surveys and rescreening were administered post-intervention completion. Results indicated that Fear-Less was an acceptable and feasible FCR intervention. Results provided preliminary support for the potential impact of Fear-Less in reducing FCR. Fear-Less is a promising first step in providing an acceptable and feasible stepped-care model to treat FCR in survivors with metastatic disease.
- 14 September 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (9) , 2969
Open AccessFeasibility and Acceptability of Fear-Less: A Stepped-Care Program to Manage Fear of Cancer Recurrence in People with Metastatic Melanoma
Immunotherapies and targeted therapies have revolutionised treatment of metastatic melanoma and improved survival rates. However, survivors treated with novel therapies are vulnerable to high levels of fear of cancer recurrence or progression (FCR). Existing FCR interventions have rarely been trialled in people with advanced cancer. The current study aimed to evaluate the acceptability and feasibility of Fear-Less: a stepped-care model to treat FCR in people with metastatic melanoma treated with immunotherapy or targeted therapy. Sixty-one outpatients with metastatic melanoma were screened using the Fear of Cancer Recurrence Inventory Short Form (FCRI-SF) and Fear of Progression Questionnaire Short Form (FoP-Q-SF). Survivors with subthreshold FCR were stratified to a self-management intervention while those with clinical levels of FCR were provided with an individual therapy, Conquer Fear. Survivor experience surveys and rescreening were administered post-intervention completion. Results indicated that Fear-Less was an acceptable and feasible FCR intervention. Results provided preliminary support for the potential impact of Fear-Less in reducing FCR. Fear-Less is a promising first step in providing an acceptable and feasible stepped-care model to treat FCR in survivors with metastatic disease.
- 20 February 2012
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 47 (10) , 1361-1365
The psychosocial impact of haematopoietic SCT on sibling donors
The physical and psychosocial consequences for patients undergoing blood SCT for the treatment of cancer and their families have been extensively documented. There has, however, been far less investigation into the psychosocial consequences for sibling donors who are both family members and undergoing an invasive medical procedure. The aim of this study was therefore to explore the psychosocial impact of PBSC donation before, during and after donation, and to gain insight into donors' experiences of the preparation for, and procedures associated with, donation. Participants included 13 men and 9 women, with a mean age of 53.1 (SD=9.4) years, who underwent PBSC or BM donation between 2007 and 2010. Data were collected via face-to-face or telephone interviews and a questionnaire. Results revealed that a broad range of both positive and negative emotions were experienced at different time points during donation. The psychosocial impact of donation was also influenced by the interactions between factors such as pragmatic aspects of the donation process; family dynamics; perceived adequacy of preparation and emotional support; and uncertainty related to health outcomes for the recipient and donor. Routine provision of psychosocial support to donors as well as recipients is therefore important.
- 20 February 2012
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 47 (10) , 1361-1365
The psychosocial impact of haematopoietic SCT on sibling donors
The physical and psychosocial consequences for patients undergoing blood SCT for the treatment of cancer and their families have been extensively documented. There has, however, been far less investigation into the psychosocial consequences for sibling donors who are both family members and undergoing an invasive medical procedure. The aim of this study was therefore to explore the psychosocial impact of PBSC donation before, during and after donation, and to gain insight into donors' experiences of the preparation for, and procedures associated with, donation. Participants included 13 men and 9 women, with a mean age of 53.1 (SD=9.4) years, who underwent PBSC or BM donation between 2007 and 2010. Data were collected via face-to-face or telephone interviews and a questionnaire. Results revealed that a broad range of both positive and negative emotions were experienced at different time points during donation. The psychosocial impact of donation was also influenced by the interactions between factors such as pragmatic aspects of the donation process; family dynamics; perceived adequacy of preparation and emotional support; and uncertainty related to health outcomes for the recipient and donor. Routine provision of psychosocial support to donors as well as recipients is therefore important.